Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Shenouda

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
European Annals of Otorhinolaryngology, Head and Neck Diseases|June 14, 2022
Aural tuberculosis at the start of the 21st century. Literature review according to SWiM guidelines. Part 1: Clinical and diagnostic dataD Malinvaud, K Shenouda, L Laccourreye, et al.
Cardiovascular Research|May 23, 2008
Ecstasy produces left ventricular dysfunction and oxidative stress in ratsSylvia K Shenouda, Kevin C Lord, Elizabeth McIlwain, et al.
Diabetes, Obesity & Metabolism|May 28, 2011
Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover studyJ K Berg, S K Shenouda, C R Heilmann, et al.
Cardiovascular Research|February 9, 2010
Oxidative stress contributes to methamphetamine-induced left ventricular dysfunctionKevin C Lord, Sylvia K Shenouda, Elizabeth McIlwain, et al.
Diabetes Care|January 29, 2011
The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargineJohn B Buse, Bruce H R Wolffenbuttel, William H Herman, et al.
Diabetes Care|March 21, 2012
Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetesJulio Rosenstock, Sylvia K Shenouda, Richard M Bergenstal, et al.
Lancet (London, England)|November 13, 2012
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyJohn B Buse, Michael Nauck, Thomas Forst, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
European Annals of Otorhinolaryngology, Head and Neck Diseases|June 14, 2022
Aural tuberculosis at the start of the 21st century. Literature review according to SWiM guidelines. Part 1: Clinical and diagnostic dataD Malinvaud, K Shenouda, L Laccourreye, et al.
Cardiovascular Research|May 23, 2008
Ecstasy produces left ventricular dysfunction and oxidative stress in ratsSylvia K Shenouda, Kevin C Lord, Elizabeth McIlwain, et al.
Diabetes, Obesity & Metabolism|May 28, 2011
Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover studyJ K Berg, S K Shenouda, C R Heilmann, et al.
Cardiovascular Research|February 9, 2010
Oxidative stress contributes to methamphetamine-induced left ventricular dysfunctionKevin C Lord, Sylvia K Shenouda, Elizabeth McIlwain, et al.
Diabetes Care|January 29, 2011
The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargineJohn B Buse, Bruce H R Wolffenbuttel, William H Herman, et al.
Diabetes Care|March 21, 2012
Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetesJulio Rosenstock, Sylvia K Shenouda, Richard M Bergenstal, et al.
Lancet (London, England)|November 13, 2012
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyJohn B Buse, Michael Nauck, Thomas Forst, et al.
Pageof 2